Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Discover how leading R&D teams use Cypris Q to monitor technology landscapes and identify opportunities faster - Book a demo Executive Summary GLP-1based obesity pharmacotherapy has evolved from single-hormone appetite suppression into a platform competition spanning poly-agonist biology, delivery convenience, and body-composition optimization
People with diabetes have much higher risks of getting cancer
Additionally, biotechnology and pharmaceutical companies are examining how to repurpose molecules implicated in skeletal muscle pathways (such as myostatin/activin, apelin, and mTOR), and developing new molecules and medications to maintain SMM while benefiting from GLP-1 medications' positive health effects
The next horizon really is going to be cancer
US$ 27.55
US$ 24.55
US$ 24.22
US$ 28.32
US$ 25.52
US$ 23.89
US$ 21.50
US$ 28.83
